Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levocetirizine + pseudoephedrine is an oral combination drug containing **levocetirizine**, a non-sedating antihistamine, and **pseudoephedrine**, a sympathomimetic nasal decongestant. Levocetirizine selectively blocks histamine H1 receptors, reducing symptoms of allergic rhinitis such as sneezing, itching, runny nose, and watery eyes. Pseudoephedrine acts on alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction, which relieves nasal and sinus congestion. The combination is commonly indicated for symptomatic relief of allergic rhinitis, sinusitis, and the common cold, especially when both allergy symptoms and nasal congestion are present[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levocetirizine + pseudoephedrine.